Black Diamond Therapeutics (BDTX) Change in Account Payables (2019 - 2026)

Black Diamond Therapeutics (BDTX) has 8 years of Change in Account Payables data on file, last reported at $2.4 million in Q1 2026.

• Quarterly Change in Account Payables rose 273.31% year-over-year to $2.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $341000.0 (down 76.19% YoY) and the FY2025 annual result came in at -$3.4 million, down 303.68% from the prior year.
• Change in Account Payables improved to $2.4 million in Q1 2026, from -$396000.0 in the prior quarter.
• In the past five years, Change in Account Payables ranged from a high of $3.5 million in Q3 2022 to a low of -$3.9 million in Q4 2022.
• A 5-year average of -$58117.6 and a median of -$343000.0 in 2023 frame the typical range for Change in Account Payables.
• The widest YoY moves for Change in Account Payables: up 463.38% in 2022, down 459.51% in 2022.
• Tracing BDTX's Change in Account Payables over 5 years: stood at -$3.9 million in 2022, then jumped by 141.98% to $1.6 million in 2023, then gained by 24.91% to $2.0 million in 2024, then tumbled by 119.45% to -$396000.0 in 2025, then surged by 703.54% to $2.4 million in 2026.
• The last three Change in Account Payables figures came in at $2.4 million (Q1 2026), -$396000.0 (Q4 2025), and $204000.0 (Q3 2025), per Business Quant data.